158
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Synthesis, Docking and Antiepileptic Activity of New 2-((1,5-Diphenyl-1H-1,2,4-Triazol-3-yl)Thio)-N-Phenylacetamide Derivatives

ORCID Icon, , ORCID Icon, , &
Pages 6429-6443 | Received 08 Mar 2021, Accepted 14 Sep 2021, Published online: 29 Sep 2021
 

Abstract

In this work, a new series of 2-((1,5-diphenyl-1H-1,2,4-triazol-3-yl)thio)-N-phenylacetamide derivatives (9a–k) were synthesized and then evaluated for their antiepileptic activity against pentylenetetrazole (PTZ)-induced seizures in mice. The most potent synthesized compound was 3-chloro derivative, 9e, with an average latency time of 825 ± 281 seconds (mean ± SEM) and zero mortality. Moreover, compound 9e was more active than phenytoin (p < 0.1) but weaker than phenobarbital (p < 0.05) in the PTZ test. Further, a molecular docking study was performed to investigate the modes of interactions between the GABAA receptor and the synthesized compounds. Docking results indicate that all of the synthesized compounds place well into the active site of the GABAA receptor. In addition, compound 9e, with the highest anticonvulsant properties, demonstrates proper interactions and forms strong hydrogen bonds with key amino acid residues in the active site of the GABAA receptor. Additionally, it has exhibited higher binding energy in the docking study compared to phenobarbital and phenytoin as the standard antiepileptic agents.

Acknowledgments

The authors would like to acknowledge Dr. Mehdi Gholami at the Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran, for kind assistance in providing laboratory facilities for this research.

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

Financially supported by the Research Council of AJA University of Medical Sciences gratefully acknowledged.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.